Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Pharmacology, Weill Cornell Medical College, New York, NY, USA; Department of Radiology, Weill Cornell Medical College, New York, NY, USA; Radiochemistry and Molecular Imaging Probes Core, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Cancer Lett. 2018 Apr 10;419:139-151. doi: 10.1016/j.canlet.2018.01.052.
The Human Epidermal Growth Factor Receptor (ErbB/HER) family - EGFR/HER1, ErbB-2/HER2, ErbB-3/HER3, and ErbB-4/HER4 - play a key role in tumor development. Moreover, positive status of HER2 and specific mutations of EGFR are necessary to initiate HER2 directed and EGFR mutation directed therapies. The status of these receptors is usually determined by assaying biopsy specimens of tumor tissues; however, tissue samples are insufficient to account for the complex dynamics and heterogeneity involved in HER status. Molecular imaging of receptors of the HER family have undergone much development, and some show promise for facilitating patient selection for HER therapy and monitoring of treatment response. This review provides a general overview of HER family expression and signaling in tumor tissue and more importantly discusses the available EGFR, HER2 and HER3 molecular imaging modalities, highlighting their use not only for selecting patients for receptor-targeted therapy, but also for monitoring therapeutic response. Additionally, the design and the biological evaluation of HER-specific imaging probes using different cancer models and clinical data are discussed.
人类表皮生长因子受体(ErbB/HER)家族 - EGFR/HER1、ErbB-2/HER2、ErbB-3/HER3 和 ErbB-4/HER4 - 在肿瘤发展中起着关键作用。此外,HER2 的阳性状态和 EGFR 的特定突变是启动 HER2 定向和 EGFR 突变定向治疗的必要条件。这些受体的状态通常通过检测肿瘤组织的活检样本来确定;然而,组织样本不足以说明 HER 状态所涉及的复杂动态和异质性。HER 家族受体的分子成像已经有了很大的发展,其中一些显示出了促进患者选择 HER 治疗和监测治疗反应的潜力。本综述提供了关于肿瘤组织中 HER 家族表达和信号转导的一般概述,更重要的是讨论了现有的 EGFR、HER2 和 HER3 分子成像方式,强调它们不仅可用于选择受体靶向治疗的患者,还可用于监测治疗反应。此外,还讨论了使用不同癌症模型和临床数据设计和生物评估 HER 特异性成像探针。